Piper Sandler raised the firm’s price target on CVS Health to $85 from $82 and keeps an Overweight rating on the shares. The firm notes CVS reiterated the 2023 outlook, established 2024 guidance and reset the company’s long-term EPS growth algorithm to achievable levels with defined paths to upside at the company’s Investor Day.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVS:
- CVS Health (NYSE:CVS) Rises on Bullish FY24 Outlook and Dividend Hike
- CVS Health increases quarterly dividend 10% to 66.5c per share
- CVS Health sees FY24 adjusted EPS at least $8.50, consensus $8.51
- CVS Health back FY23 adjusted EPS view $8.50-$8.70, consensus $8.58
- CVS Health to introduce new pharmacy reimbursement model
